Life Chemicals is pleased to announce its collaboration with Variational AI aimed at the design and synthesis of cutting-edge target-selective small molecule screening libraries. By targeting critical kinases and GPCRs with the help of AI-driven de novo compound generation, this bilateral collaboration will provide remarkably efficient tools for your drug discovery projects.
Unparalleled speed, precision, and innovation will be brought into your research by coupling our diverse and extensive HTS Compound Collection with Variational AI’s Enki™ generative AI platform! On top of that, our Custom Synthesis Services will further streamline your workflow from design to compound screening!
The first product of this collaboration is a unique EGFR AI-enhanced Screening Compound Library featuring over 2,500 drug-like compounds with predicted EGFR ATP-site inhibitory activity. Just a promising beginning to unlocking Life Chemicals' potential to contribute to your screening campaigns!
Enki™ Generative AI Platform Enhancing Drug Discovery
Delivering exceptional speed and accuracy, the Enki™ platform leverages state-of-the-art machine learning models to generate and optimize novel compounds. Furthermore, drawing on a dataset of over 400 million experimental and computational data points, Enki™ paves the way to the next level of lead generation and optimization in drug discovery.
A Growing List of Kinase and GPCR Targets
Together, we can supply an ever-expanding list of kinase and GPCR targets, custom-designed using AI. With our range of drug targets continuously growing, we absolutely welcome any inquiries to address your specific target needs.
Take Your Screening Projects to the Next Level with AI!
Harness the combined expertise of Life Chemicals and Variational AI to propel your research forward. Ready to explore AI-powered screening libraries? Contact us at marketing@lifechemicals.com and discover how we can boost your drug discovery endeavor.